A quick look at the best Black Friday Lego deals:
…
Earlier treatment options, such as vorasidenib (Vorangio), could address unmet needs for patients with slow-growing IDH-mutant gliomas, according to real-world data reported in a poster presented during the 2025 Society for Neuro-Oncology Annual Meeting.
In the study, vorasidenib treatments demonstrated minimal toxicity for patients with slow-growing IDH-mutant gliomas researchers have reported— with a treatment approved in 2024 by the FDA, possibly helping to address this issue.
Real-world observation rates and treatment patterns among patients aged 12 years and older with IDH-mutated glioma and their implications for targeted therapy use were reported.
Researchers reported that 5,894 with IDH-mutant glioma were identified, of whom 3,212, or 54%, had grade 2 tumors and 2,682, or 46%, had grade 3 tumors. The median age at diagnosis was 39 (range 31-50) years.
After initial surgery, 2,058 patients were on observation, and 3,660 initiated therapies within 90 days. Of the former group, 1,568 remained on observation until the end of the study period in 2022, while 490 received chemotherapy/radiation after an initial period of observation.
By 90 days after surgery, 70% of patients who were age 40 years or older had initiated therapy, compared with 57% of those aged 12 to 39 years. At 90 days, 43% of patients age 12 to 39 years and 30% of patients age 40 years or older remained on observation, with 34% and approximately 22%, respectively, still on observation after 5 years.
Additionally, by 90 days following surgery, 47% of patients with a grade 2 glioma and 82% of patients with a grade 3 glioma had initiated therapy, and at 90 days 53% of patients with a grade 2 glioma and 18% with a grade 3 glioma remained on observation, with 43% and 10%, respectively, still on observation after 5 years.
“Historical management patterns show that a substantial proportion of patients with [IDH]-mutated glioma were managed with observation, suggesting an unmet need for an effective early intervention,” researchers concluded in their poster presentation of the data. “While younger patients (aged 12 to 39 years) and those with World Health Organization (WHO) grade 2 glioma were more likely to undergo observation, a substantial proportion of patients aged [at least] 40 years and those with WHO grade 3 glioma also underwent observation.”
Researchers further noted that the fact that patients age 40 years and older or those with grade 3 glioma received radiation or chemotherapy, given those treatments’ well-established long-term adverse effects, should highlight the need for less-toxic alternative treatment options.
Vorasidenib, researchers stated in the poster “offers an early, effective, low-toxicity treatment option across these patient groups.”
Vorasidenib was approved the FDA in August 2024 for the treatment of adult and pediatric patients at least 12 years old with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection. An IDH1 and IDH2 inhibitor, vorasidenib was the first systemic therapy approved by the agency for patients with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation, according to a notice from the FDA.
Additionally, longer-term results announced earlier this month showed that vorasidenib continued to benefits patients in this population, according to updated phase 3 INDIGO trial data published in The Lancet Oncology.
At a median follow-up of 20.1 months, patients treated with vorasidenib experienced superior progression-free survival to those who received placebo, with disease progression in 32% of patients who received the drug and 64% of those who did not.
There is growing interest in the astronomical object called 3I/ATLAS. What is 3I/ATLAS? Why all the interest in 3I/ATLAS? And how should creationists respond to the reports and claims made about 3I/ATLAS?
3I/ATLAS…
NVIDIA Corporation (NASDAQ:NVDA) is one of the AI Stocks Making Headlines on Wall Street. On November 25, Bank of America maintained a positive outlook on the stock, along with AMD and Broadcom, despite intensifying competition in the artificial intelligence chip market.
The reiterated buys follows reports that Meta (META) is considering using Google’s (GOOG) TPUs in addition to its existing Nvidia GPU supply.
“Late yesterday, media reports indicated the possibility of Google renting out the TPUs to Meta next year, potentially followed by on-premise deployments (with Meta and maybe others) in 2027. Neither company has made any official comments regarding any such transaction, but if true, it can intensify the competitive landscape for Meta’s current GPU suppliers NVDA and AMD.” – Bank of America analyst Vivek Arya.
A data analyst with a headset, looking intently at the information unfolding on her screen.
In response, Nvidia issued a statement contending that it is still the leader in the market.
“NVIDIA is a generation ahead of the industry — it’s the only platform that runs every AI model and does it everywhere computing is done. NVIDIA offers greater performance, versatility, and fungibility than ASICs, which are designed for specific AI frameworks or functions.”
According to Arya, Nvidia will still likely dominate the market, albeit at a 75% market share from the estimated 85% it currently holds.
NVIDIA Corporation (NASDAQ:NVDA) specializes in AI-driven solutions, offering platforms for data centers, self-driving cars, robotics, and cloud services.
While we acknowledge the potential of NVDA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 AI Stocks in Focus on Wall Street and 10 Hot AI Stocks to Keep on Your Radar
Disclosure: None.
Ever wondered if National Grid is actually good value for your portfolio, or if you might be missing out on a hidden opportunity? You are not alone, especially with all the chatter around its share price lately.
After a steady period, National Grid shares have climbed 0.7% over the past week and are now up an eye-catching 19.4% year-to-date. That sort of momentum often sparks fresh debates about growth potential and risk.
This renewed interest is backed by recent headlines. Sector-wide shifts in UK utility regulation and debates about energy infrastructure investments have all helped to keep National Grid in the spotlight. Even speculation about future policy changes has added a twist to the company’s market sentiment this year.
On the valuation front, National Grid currently has a 3 out of 6 valuation score, meaning it passes half of the simple undervalued checks we look for. Before you decide whether that score tells the full valuation story, let’s break down how value is assessed and explore a smarter way to look at a stock’s true worth by the end of this article.
Find out why National Grid’s 20.6% return over the last year is lagging behind its peers.
The Dividend Discount Model (DDM) is a valuation method that estimates a company’s intrinsic value based on projected future dividends, assuming those dividends continue to grow at a sustainable rate. This model is most useful for companies like National Grid, which have a stable dividend history and predictable payout patterns.
For National Grid, the recent dividend per share is £0.50, with a payout ratio of 52.7%. Analysts expect dividends to grow at a capped rate of 2.99%, slightly below the company’s average growth of 3.8% and overall expectations of 3.8%. Return on equity stands at a solid 8.03%, supporting both the current payout and potential for long-term increases.
Applying the DDM, National Grid’s estimated intrinsic value is £12.16 per share. This is about 5.8% higher than its current price. This suggests the market price reflects the company’s ability to deliver reliable and growing dividends, with a modest undervaluation according to this approach.
Result: ABOUT RIGHT
National Grid is fairly valued according to our Dividend Discount Model (DDM), but this can change at a moment’s notice. Track the value in your watchlist or portfolio and be alerted on when to act.
Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for National Grid.
The Price-to-Earnings (PE) ratio is a widely used metric for valuing established, profitable companies like National Grid that generate consistent earnings. It summarizes how much investors are willing to pay for each pound of current earnings and offers a practical snapshot of market expectations.
NEW DELHI, Nov. 29 (Xinhua) — Private airlines in India said on Saturday that their teams of engineers were working on upgrading the necessary software updates in their respective A320 fleet, after Airbus issued a technical advisory for the global A320 fleet citing affects of solar radiation on flights controls.
The issue arose after the European Union Aviation Safety Agency (EASA) issued an emergency airworthiness directive (EAD) to operators to ensure their aircraft had “serviceable” Elevator and Aileron Computers before further flights.
As per the Airbus, nearly 6000 A320 flights globally were affected by the technical glitch. Aviation experts said that it was a serious technical glitch and airline companies could take 7-8 hours to complete the software upgrading process.
India’s private airline IndiGo announced that its engineers had already completed the mandatory Airbus safety update on 160 out of 200 AIB mandated A320-family aircraft.
Similarly, India’s another private airline “Air India” too announced that its engineers were working on upgrading the software in the A320 fleet, and that it was already reset in 40 percent of its impacted flights. ■
